Gyre Therapeutics (GYRE) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, losing 3.2% versus a loss of 39.0%. Over five years, IVA leads with a -74.9% price change compared with -88.3% for GYRE. Inventiva S.A. American Depository Shares is the larger company by market cap ($784.3 million vs $716.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | IVA |
|---|---|---|
| Share price | $6.76 | $3.32 |
| Market cap | $716.79M | $784.25M |
| 1-day change | -3.98% | -1.34% |
| YTD return | -0.28% | -27.63% |
| 1-year return | -3.16% | -39.04% |
| 5-year return | -88.27% | -74.89% |
| Forward P/E | 112.67 | — |
| EPS (TTM) | $-0.25 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $7.98 |
| 52-week low | $5.44 | $3.11 |
| Distance from 52-week high | -28.24% | -58.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.18% | +357.83% |
| Average volume | 105.59K | 1.38M |
| Shares outstanding | 106.03M | 236.22M |
| Employees | 625 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed IVA by 35.9 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
GYRE vs IVA FAQ
Which is bigger, Gyre Therapeutics or Inventiva S.A. American Depository Shares?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $784.25M compared with $716.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or IVA?
GYRE returned -3.16% over the past 12 months, compared with -39.04% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.